Tag: Biosimilar
“There are inconstancies across biosimilar classes right now”
Thomas Newcomer, VP, Head of US Market Access, Samsung Bioepis shares insightful perspectives on the US and Indian biosimilar markets
Glenmark becomes first to launch biosimilar of popular anti‐diabetic drug, Liraglutide,...
Lirafit™ will sharply lower the daily cost of therapy by around 70% to around Rs 100; making the drug more accessible to a larger number of patients with type 2 diabetes mellitus in the country
Biocon Biologics appoints Sandoz as distributor for Adalimumab BS Subcutaneous Injection...
Adalimumab BS for subcutaneous injection [FKB] is a biosimilar of Humira® (generic name: adalimumab (genetical recombination)) and is indicated for immune-related diseases
Biocon Biologics receives MHRA, UK approval for YESAFILI, a biosimilar of...
In September, YESAFILI®, received marketing authorization approval from the European Commission (EC) for the European Union (EU)
Lupin and Amman Pharma sign exclusive licensing & supply agreement for...
Both Lupin and Amman Pharma are united in their mission to provide innovative, high-quality healthcare solutions to patients in the MENA region
Biocon Biologics announces positive CHMP opinion for its biosimilar to treat...
The CHMP positive opinion will be considered by the European Commission whose decision on the approval is expected by the end of September 2023
Enzene Biosciences launches Cetuximab: the first biosimilar of cancer treatment drug...
Cetuximab is the first biosimilar in the world, of cancer treatment drug Erbitux
Lupin’s Rymti gets approval from Canadian regulator
Rymti is Lupin’s biosimilar etanercept approved for all indications of the reference product, Enbrel
ICT Mumbai to hold annual biosimilar workshop on 4-8 October
To be held in virtual mode as a 4-part webinar series organized over a span of 5 days, the workshop will impart training and insight directly from experts and academicians of the biopharmaceutical, diagnostic and vaccine industries.................
Lupin gets US-FDA nod for its Pegfilgrastim biosimilar application
The Biologics License Application (BLA) submission is supported by similarity data from analytical, pharmacokinetic, pharmacodynamic and immunogenicity studies........................